Is Paxlovid Still Worth It?
- PMID: 38412357
- DOI: 10.1093/cid/ciae106
Is Paxlovid Still Worth It?
Keywords: Covid-19; Nirmatrelvir/ritonavir; Paxlovid; SARS-CoV-2; costs.
Conflict of interest statement
Potential conflicts of interest. G. M.-K. reports funds awarded for the PANDA trial, paid to institution, from the Medical Research Future Fund; payments for travel from University of Wollongong and New South Wales Health; and unpaid leadership or fiduciary role with Australian Skeptics, Inc. J. S. F. reports payment for expert testimony from the Board of Medicine, Maine (author testified in a hearing about evidence-based practices related to COVID-19; author does not specifically remember whether Paxlovid was discussed, but in that context, author's testimony would have been that Paxlovid was found in at least 1 high-quality randomized placebo-controlled trial to be an important and effective treatment in preventing severe COVID-19 outcomes). All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment on
-
Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19.Clin Infect Dis. 2024 Jul 19;79(1):108-110. doi: 10.1093/cid/ciae105. Clin Infect Dis. 2024. PMID: 38411622 Free PMC article.
Similar articles
-
Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.Rev Esp Quimioter. 2022 Aug;35(4):357-361. doi: 10.37201/req/054.2022. Epub 2022 Jul 13. Rev Esp Quimioter. 2022. PMID: 35822605 Free PMC article.
-
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?Biomed Pharmacother. 2023 Jun;162:114367. doi: 10.1016/j.biopha.2023.114367. Epub 2023 Feb 6. Biomed Pharmacother. 2023. PMID: 37018987 Free PMC article. Review.
-
Optimizing the use of Paxlovid in clinical practice.Drugs Today (Barc). 2022 Nov;58(11):539-546. doi: 10.1358/dot.2022.58.11.3461265. Drugs Today (Barc). 2022. PMID: 36422515
-
The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between Mpro and antiviral drugs (nirmatrelvir and ritonavir).Adv Med Sci. 2023 Mar;68(1):1-9. doi: 10.1016/j.advms.2022.10.001. Epub 2022 Nov 2. Adv Med Sci. 2023. PMID: 36368287 Free PMC article.
-
[Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination].Rev Esp Quimioter. 2022 Jun;35(3):236-240. doi: 10.37201/req/002.2022. Epub 2022 Feb 21. Rev Esp Quimioter. 2022. PMID: 35183067 Free PMC article. Review. Spanish.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous